Alligator Bioscience AB (publ) (OSE: CARA) Q2 2025 Earnings | 07/10/2025

About this video

Alligator Bioscience AB (publ) reported its Q2 2025 results on July 10, 2025, highlighting continued progress in its immuno-oncology pipeline, key regulatory milestones, and strengthened financial flexibility. Q2 2025 Financial Highlights Net Sales: SEK 0 (Q2 2025), compared to SEK 7.6 million in Q2 2024 Operating Loss: SEK 22.3 million, a significant improvement from SEK 47.4 million in Q2 2024 Net Loss for the Period: SEK 1.7 million, compared to SEK 49.2 million in Q2 2024 EBITDA: Not specified for the quarter Cash and Cash Equivalents: SEK 33.9 million at quarter-end, down from SEK 77.5 million a year ago Earnings Per Share: SEK -0.08 (Q2 2025), compared to SEK -66.36 (Q2 2024) Operational and Strategic Highlights Successfully completed the TO 12 warrant program in May 2025, raising SEK 61 million before costs and partially repaying loans, strengthening the financial position. Completed GMP manufacturing of mitazalimab for the upcoming Phase 3 trial, ensuring supply readiness. Received a paediatric waiver and positive protocol advice from the EMA, and FDA confirmation of the Phase 3 dose for mitazalimab, keeping the program on track for initiation with a development partner. Shanghai Henlius initiated a Phase 2 clinical trial for HLX22 in HER2-positive breast cancer, which also received EU Orphan Drug Designation for gastric cancer. Ongoing restructuring and cost control measures, with a target to reduce operational costs to SEK 20–25 million per quarter in the second half of 2025. Outlook Focused on securing a strategic partner and initiating the Phase 3 trial for mitazalimab. Continued emphasis on cost reduction, operational efficiency, and maintaining financial flexibility through the end of 2025. Advancing additional pipeline assets and exploring further collaborations and licensing opportunities. About Inside Ticker: For more expert analysis and real-time updates on Alligator Bioscience AB (publ) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #AlligatorBioscience #ATORX #q22025 #earnings #ImmunoOncology #Mitazalimab #HLX22 #FinancialResults #ClinicalTrials #innovation #Biotech #Healthcare #Growth #operationalefficiency #costcontrol #investorupdate #insideticker #RegulatoryMilestones #pipeline #strategicpartnerships #oncology